Distinct immunologic vs progenitor landscapes in myeloid leukemia recurrence: Adaptive immune persistence in pediatrics vs niche exhaustion in adults.

10021 Background: Recurrent myeloid leukemia remains a therapeutic challenge with distinct clinical trajectories across age groups. While our parallel study identified a "universal adipogenic shift" in the marrow stroma common to all ages, the specific cellular drivers distinguishing pediatric from adult relapse remain undefined. We hypothesized that against this shared stromal background, the mechanism of recurrence diverges: the pediatric marrow mounts an adaptive immune response, whereas the aging adult marrow suffers from hematopoietic reservoir depletion. Methods: We analyzed the tumor microenvironment (TME) of 2,378 myeloid leukemia samples (2,007 primary, 371 recurrent) using xCell transcriptomic deconvolution. The cohort was stratified into Pediatric (< 18y, n = 2,071) and Adult ( ≥ 18y, n = 307) subgroups to control for ontogenic baselines. We compared differential expression rankings between primary and recurrent states using Mann-Whitney U tests with Bonferroni correction (Padj) to identify age-specific dominance in TME remodeling. Results: Comparative analysis revealed divergent TME landscapes between age groups. In pediatrics, recurrence was characterized by an "Immune-Adaptive" program; CD4+ Memory T-cells were the dominant signature (rank 4, p < 10⁻²⁷), alongside significant increases in Preadipocytes ( p < 10⁻⁴⁹) and pro-B cells. Conversely, adult recurrence exhibited "Niche Exhaustion," primarily losing hematopoietic progenitors (CMP/GMP, p <10⁻⁷) and mesenchymal stem cells (MSC, p < 10⁻⁹). While CD4+ Memory T-cells increased in adults, the signal was less prominent (rank 18, p < 10⁻⁵). Both groups shared significant vascular collapse (Pericyte loss, p < 10⁻⁷), identifying it as a universal hallmark of relapse. Conclusions: Myeloid leukemia recurrence is driven by age-distinct microenvironmental remodeling. Pediatric relapse is defined by immune adaptation and adipogenesis, while adult relapse is characterized by progenitor and niche exhaustion. Vascular collapse represents a universal therapeutic target. These findings suggest that immunotherapy and niche-directed treatments must be tailored to the patient’s age-specific TME landscape to improve outcomes. Top age-specific trends in recurrent vs. primary myeloid leukemias. Cohort Cell Type Direction Mean Diff (Rec - Pri) Padj Pediatric (<18y) Pericytes Primary- High -0.085 P < 0.05 Preadipocytes Recurrence- High +0.064 P < 0.05 MSC Primary- High -0.099 P < 0.05 CD4+ Memory T-cells Recurrence- High +0.849 P < 0.05 pro-B cells Recurrence- High +0.301 P < 0.05 Adult (≥18y) MSC Primary- High -0.165 P < 0.05 Pericytes Primary- High -0.078 P < 0.05 CMP Primary- High -0.526 P < 0.05 Smooth muscle Primary- High -0.094 P < 0.05 GMP Primary- High -0.765 P < 0.05 CD4+ Memory T-cells* Recurrence- High +1.184 P < 0.05 *Manually added row for comparison purposes.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-27
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.10021
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Distinct immunologic vs progenitor landscapes in myeloid leukemia recurrence: Adaptive immune persistence in pediatrics vs niche exhaustion in adults.

Katharine Thomas, Vera Vaz, Karen Dong-Tran, Thomas Noonan et al.
Journal of Clinical Oncology
Acute Myeloid Leukemia Research
article

Distinct immunologic vs progenitor landscapes in myeloid leukemia recurrence: Adaptive immune persistence in pediatrics vs niche exhaustion in adults.

Katharine Thomas, Vera Vaz, Karen Dong-Tran, Thomas Noonan, Neil Arya Babu
article en

Abstract

10021 Background: Recurrent myeloid leukemia remains a therapeutic challenge with distinct clinical trajectories across age groups. While our parallel study identified a "universal adipogenic shift" in the marrow stroma common to all ages, the specific cellular drivers distinguishing pediatric from adult relapse remain undefined. We hypothesized that against this shared stromal background, the mechanism of recurrence diverges: the pediatric marrow mounts an adaptive immune response, whereas the aging adult marrow suffers from hematopoietic reservoir depletion. Methods: We analyzed the tumor microenvironment (TME) of 2,378 myeloid leukemia samples (2,007 primary, 371 recurrent) using xCell transcriptomic deconvolution. The cohort was stratified into Pediatric (< 18y, n = 2,071) and Adult ( ≥ 18y, n = 307) subgroups to control for ontogenic baselines. We compared differential expression rankings between primary and recurrent states using Mann-Whitney U tests with Bonferroni correction (Padj) to identify age-specific dominance in TME remodeling. Results: Comparative analysis revealed divergent TME landscapes between age groups. In pediatrics, recurrence was characterized by an "Immune-Adaptive" program; CD4+ Memory T-cells were the dominant signature (rank 4, p < 10⁻²⁷), alongside significant increases in Preadipocytes ( p < 10⁻⁴⁹) and pro-B cells. Conversely, adult recurrence exhibited "Niche Exhaustion," primarily losing hematopoietic progenitors (CMP/GMP, p <10⁻⁷) and mesenchymal stem cells (MSC, p < 10⁻⁹). While CD4+ Memory T-cells increased in adults, the signal was less prominent (rank 18, p < 10⁻⁵). Both groups shared significant vascular collapse (Pericyte loss, p < 10⁻⁷), identifying it as a universal hallmark of relapse. Conclusions: Myeloid leukemia recurrence is driven by age-distinct microenvironmental remodeling. Pediatric relapse is defined by immune adaptation and adipogenesis, while adult relapse is characterized by progenitor and niche exhaustion. Vascular collapse represents a universal therapeutic target. These findings suggest that immunotherapy and niche-directed treatments must be tailored to the patient’s age-specific TME landscape to improve outcomes. Top age-specific trends in recurrent vs. primary myeloid leukemias. Cohort Cell Type Direction Mean Diff (Rec - Pri) Padj Pediatric (<18y) Pericytes Primary- High -0.085 P < 0.05 Preadipocytes Recurrence- High +0.064 P < 0.05 MSC Primary- High -0.099 P < 0.05 CD4+ Memory T-cells Recurrence- High +0.849 P < 0.05 pro-B cells Recurrence- High +0.301 P < 0.05 Adult (≥18y) MSC Primary- High -0.165 P < 0.05 Pericytes Primary- High -0.078 P < 0.05 CMP Primary- High -0.526 P < 0.05 Smooth muscle Primary- High -0.094 P < 0.05 GMP Primary- High -0.765 P < 0.05 CD4+ Memory T-cells* Recurrence- High +1.184 P < 0.05 *Manually added row for comparison purposes.

Journal of Clinical OncologyVol. 44(16_suppl)
University of Nevada, Reno (US), Renown Health (US), Renown Regional Medical Center (US)
Openalex Percentile: Top 8%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.